

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4703969

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE (REEL 040913 / FRAME 0118)
CONVEYING PARTY DATA	
Name	Execution Date
CITIBANK, N.A.	11/21/2017
RECEIVING PARTY DATA	
Name:	RELIABLE BIOPHARMACEUTICAL, LLC
Street Address:	1945 WALTON ROAD
City:	OVERLAND
State/Country:	MISSOURI
Postal Code:	63114
PROPERTY NUMBERS Total: 9	
Property Type	Number
Patent Number:	6252061
Patent Number:	6596858
Patent Number:	7393954
Patent Number:	8288515
Patent Number:	8420790
Patent Number:	8703923
Patent Number:	8987430
Patent Number:	8859522
Patent Number:	9255119
CORRESPONDENCE DATA	
Fax Number:	(800)914-4240
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	800-713-0755
Email:	Michael.Violet@wolterskluwer.com
Correspondent Name:	CT CORPORATION
Address Line 1:	4400 EASTON COMMONS WAY
Address Line 2:	SUITE 125
Address Line 4:	COLUMBUS, OHIO 43219
NAME OF SUBMITTER:	DORIS KA
SIGNATURE:	/Doris Ka/

PATENT

DATE SIGNED:	11/27/2017
Total Attachments: 4 source=10VWR (Payoff) - Patent Release (Reliable Biopharmaceutical, LLC) (Executed)#page1.tif source=10VWR (Payoff) - Patent Release (Reliable Biopharmaceutical, LLC) (Executed)#page2.tif source=10VWR (Payoff) - Patent Release (Reliable Biopharmaceutical, LLC) (Executed)#page3.tif source=10VWR (Payoff) - Patent Release (Reliable Biopharmaceutical, LLC) (Executed)#page4.tif	

RECORDATION FORM COVER SHEET

PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

Citibank, N.A.

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance/Execution Date(s):

Execution Date(s) November 21, 2017

- ☐ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Joint Research Agreement
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☒ Other Release (Reel 040913 / Frame 0118)

2. Name and address of receiving party(ies)

Name: Reliable Biopharmaceutical, LLC

Internal Address: _____

Street Address: 1945 Walton Road

City: Overland

State: MO

Country: USA Zip: 63114

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application or patent number(s):

☐ This document is being filed together with a new application.

A. Patent Application No.(s)

B. Patent No.(s)

See attached Schedule I

Additional numbers attached? ☒ Yes ☐ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Doris Ka, Legal Assistant

Internal Address: Cahill Gordon & Reindel LLP

Street Address: 80 Pine Street

City: New York

State: NY Zip: 10005

Phone Number: 212-701-3569

Docket Number: 30860.623

Email Address: dka@cahill.com

6. Total number of applications and patents involved: 9

7. Total fee (37 CFR 1.21(h) & 3.41) \$ _____

- ☐ Authorized to be charged to deposit account
☐ Enclosed
☐ None required (government interest not affecting title)

8. Payment Information

Deposit Account Number _____

Authorized User Name _____

9. Signature: Doris Ka

Signature

November 22, 2017

Date

Doris Ka

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents: 4

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

RELEASE OF SECURITY INTEREST IN PATENTS

This RELEASE OF SECURITY INTEREST IN PATENTS (this “Release”), dated as of November 21, 2017 (the “Effective Date”), is made by CITIBANK, N.A., in its capacity as collateral agent (the “Agent”), in favor of RELIABLE BIOPHARMACEUTICAL, LLC (the “Grantor”).

WHEREAS, pursuant to that certain Guarantee and Collateral Agreement dated as of September 28, 2015 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Guarantee and Collateral Agreement”), the Grantor granted to the Agent, in its capacity as Agent, a security interest in and to certain collateral;

WHEREAS, pursuant to the Guarantee and Collateral Agreement, the Grantor executed and delivered a Patent Security Agreement, dated as of December 13, 2016 (the “Patent Security Agreement”), for recordal with the United States Patent and Trademark Office;

WHEREAS, the Patent Security Agreement was recorded with the United States Patent and Trademark Office on December 14, 2016 at Reel/Frame 040913/0118;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Guarantee and Collateral Agreement or the Patent Security Agreements, as applicable.

2. Release. The Agent, without representation or warranty of any kind, hereby releases, discharges, terminates and cancels all of its security interest in and to all of the Grantor’s right, title and interest in or to the Patent Collateral, including the patents and patent applications set forth on Schedule I attached hereto, arising under the Guarantee and Collateral Agreement and the Patent Security Agreement, and any and all right, title and interest of the Agent in and to the Patent Collateral shall hereby terminate, cease and become void.


3. Termination. The Agent, without representation or warranty of any kind, terminates and cancels the Patent Security Agreement.

4. Further Assurances. The Agent agrees to take all further actions, and provide to the Grantor and its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Grantor, at the Grantor’s sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

5. Governing Law. This Release shall be governed exclusively under the laws of the State of New York, without regard to conflicts of law or choice of law principles.

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

CITIBANK, N.A., acting in its capacity as
Collateral Agent

By: 
Name: _____
Title: _____ Akshay Kulkarni
Vice President

[Signature Page to Patent Release]

Schedule I

Release of Patent Security Agreement recorded December 14, 2016 at reel/frame 040913/0118

U.S. Patents and Applications:

title	Jurisdiction	Application No.	Patent No.	Status	Owner
process for the production of 2-halo-6-aminopurine derivatives	U.S.	09274518	6252061	In force	Reliable Biopharmaceutical, LLC
process for the production of 2-halo-6-aminopurine derivatives	U.S.	09803765	6596858	In force	Reliable Biopharmaceutical, LLC
process for the production of pentostatin aglycone and pentostatin	U.S.	10734545	7393954	In force	Reliable Biopharmaceutical, LLC
process for preparing fondaparinux sodium and intermediates useful in the synthesis thereof	U.S.	12847719	8288515	In force	Reliable Biopharmaceutical, LLC
efficient and scalable process for the manufacture of fondaparinux sodium	U.S.	12915864	8420790	In force	Reliable Biopharmaceutical, LLC
process for perparing fondaparinux sodium and intermediates useful in the synthesis thereof	U.S.	13618786	8703923	In force	Reliable Biopharmaceutical, LLC
efficient and scalable process for the manufacture of fondaparinux sodium	U.S.	13791178	8987430	In force	Reliable Biopharmaceutical, LLC
processes for the preparation of regadenoson and a new crystalline form thereof	U.S.	14112173	8859522	In force	Reliable Biopharmaceutical, LLC
process for perparing fondaparinux sodium and intermediates useful in the synthesis thereof	U.S.	14256235	9255119	In force	Reliable Biopharmaceutical, LLC